1.Data analysis of resolution discrepancies in minipool nucleic acid testing: A 2024 national study of Chinese blood stations
Ying YAN ; Qing HE ; Wei ZHENG ; Jie MA ; Le CHANG ; Huimin JI ; Huizhen SUN ; Lunan WANG
Chinese Journal of Blood Transfusion 2026;39(4):423-429
Objective: To investigate the incidence, characteristics, and influencing factors of resolution discrepancies within the minipool (MP) testing model across Chinese blood station laboratories in 2024. Methods: A nationwide, multicenter, cross-sectional study was conducted, including 334 blood station laboratories that reported nucleic acid reactive data among enzyme immunoassay non-reactive samples. Of these, 296 laboratories adopted the pool resolution model, with a total of 12 536 273 samples tested. Systematic analysis was performed on resolution data, focusing on the MP-NAT reactivity rate, the pool resolution concordance rate, and the resolution discrepancy rate. Subgroup analyses were conducted based on reagent types, viral targets, and Ct values. Potential causes were further explored through laboratory surveys and re-examination of raw amplification curves. Results: In 2024, the national average MP-NAT reactivity rate was 0.15%. The overall pool resolution concordance rate was 57.86%, which showed a gradual decline as Ct values increased across all reagents. The national average resolution discrepancy rate was 0.081‱(102/12 536 273), with 17.91%(53/296) of laboratories reporting at least one discrepancy. Nine reagent types were associated with these events, exhibiting reagent-specific patterns. For Reagent A2, the predominant discrepancy was HBV reactive pools resolving as HIV (36.36%); for Reagent D1, HBV pools frequently resolved as HCV (38.89%); and for Reagent E, the most common pattern was HIV pools resolving as HBV (48.00%). These resolution discrepancies were strongly associated with high Ct values: the median pool Ct for HBV exceeded 38, while those for HCV and HIV both exceeded 40. Investigations across 16 laboratories revealed that most discrepant samples exhibited “tailing” amplification curves, with some cases linked to cross-contamination or reagent batch-specific issues. Conclusion: While the incidence of resolution discrepancies in the MP-NAT model remains low in China, variations exist across different reagents and laboratories. These discrepancies are closely associated with low viral load, reagent performance, and laboratory operational practices.
2.Research progress on the effects of processing on the chemical constituents and pharmacological effects of Morinda officinalis
Na BAI ; Tianyi FU ; Yale MA ; Chen WANG ; Hongwei LI ; Kai LI ; Le KANG ; Mengyun LIU
China Pharmacy 2026;37(13):1778-1783
Morinda officinalis is one of the “Four Great Southern Medicines” and is commonly used in clinical practice to treat erectile dysfunction and nocturnal emissions caused by kidney yang deficiency, uterine cold infertility, menstrual disorders, low abdominal pain, rheumatism, and muscle and bone weakness. Based on the principle of “treating raw and cooked differently”, this article summarizes the effects of different processing methods on the chemical constituents and pharmacological effects of M. officinalis . Research has found that processing can affect the content and structure of sugars, iridoids, and anthraquinones in M. officinalis , thereby regulating its pharmacological effects such as anti-osteoporosis, immune regulation, anti-fatigue, and anti-depression. Among them, salt M. officinalis shows outstanding performance in anti-osteoporosis and enhancing immunity. Although previous studies have preliminarily elucidated the major chemical constituents of M. officinalis and their pharmacological characteristics, the dynamic transformation paths of constituents during the processing remain to be further clarified, especially the es tablishment of a quality marker system associated with the processing technology, to achieve the precision and intelligent development of the processing.
3.Research progress on the effects of processing on the chemical constituents and pharmacological effects of Morinda officinalis
Na BAI ; Tianyi FU ; Yale MA ; Chen WANG ; Hongwei LI ; Kai LI ; Le KANG ; Mengyun LIU
China Pharmacy 2026;37(13):1778-1783
Morinda officinalis is one of the “Four Great Southern Medicines” and is commonly used in clinical practice to treat erectile dysfunction and nocturnal emissions caused by kidney yang deficiency, uterine cold infertility, menstrual disorders, low abdominal pain, rheumatism, and muscle and bone weakness. Based on the principle of “treating raw and cooked differently”, this article summarizes the effects of different processing methods on the chemical constituents and pharmacological effects of M. officinalis . Research has found that processing can affect the content and structure of sugars, iridoids, and anthraquinones in M. officinalis , thereby regulating its pharmacological effects such as anti-osteoporosis, immune regulation, anti-fatigue, and anti-depression. Among them, salt M. officinalis shows outstanding performance in anti-osteoporosis and enhancing immunity. Although previous studies have preliminarily elucidated the major chemical constituents of M. officinalis and their pharmacological characteristics, the dynamic transformation paths of constituents during the processing remain to be further clarified, especially the es tablishment of a quality marker system associated with the processing technology, to achieve the precision and intelligent development of the processing.
4.Mechanisms and Clinical Research Advances of Curcumin in Modulation of Hyperlipidemia
Zhijun ZENG ; Wenjie LU ; Xiaoxue MA ; Yanhua JI ; Yun TONG ; Siyu LING ; Yue ZENG ; Chao LE ; Shaohua WANG
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(18):325-334
Hyperlipidemia is a common metabolic disorder driven by dysregulated lipid metabolism, whose pathological progression involves multifaceted interactions across various signaling pathways, including disrupted cholesterol homeostasis, insulin resistance, chronic inflammation, and oxidative stress. Although existing clinical medications such as statins can effectively reduce low-density lipoprotein cholesterol through single-target inhibition, significant limitations remain in comprehensively improving reverse cholesterol transport, metabolic inflammation, and coordinated regulation of glucose and lipid metabolism. Curcumin, the primary polyphenolic active compound derived from the traditional medicinal herb turmeric, exhibits multi-dimensional pharmacological effects including modulation of lipid metabolism, improvement of insulin sensitivity, suppression of inflammatory responses, and enhancement of antioxidant defense. This review systematically integrates the multi-target regulatory network of curcumin, elucidating its key mechanisms: Balancing the low density lipoprotein receptor/proprotein convertase subtilisin/kexin type 9 (LDLR/PCSK9) signaling pathway to promote reverse cholesterol transport, activating peroxisome proliferator-activated receptor α/γ (PPARα/γ) signaling pathways to coordinate glucolipid metabolic homeostasis, remodeling the gut microbiota-bile acid axis, inhibiting nuclear factor kappa-B (NF-κB)-mediated inflammatory responses, and activating the nuclear factor erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE) antioxidant signaling pathway. Furthermore, supported by clinical research data, the review validates curcumin's therapeutic potential in reducing total cholesterol (TC) and triglyceride (TG) levels, increasing high-density lipoprotein cholesterol (HDL-C), as well as improving vascular endothelial function and insulin sensitivity. The study highlights the multi-target regulatory properties of curcumin and discusses future clinical applications based on nano-delivery systems and personalized treatment strategies, providing a theoretical basis and novel insights for the prevention and treatment of hyperlipidemia and related metabolic disorders.
5.Incidence and Mortality of Female Breast Cancer in Zhejiang Cancer Registration Areas in 2021 and Trends from 2000 to 2021
Yan LI ; Hongrui HUANG ; Xu MA ; Dan LUO ; Le WANG ; Huizhang LI ; Lingbin DU ; Yiping WU ; Yanfei QIU
China Cancer 2025;34(10):764-774
[Purpose]To analyze the incidence and mortality of female breast cancer in Zhejiang cancer registration areas in 2021 and the trends from 2000 to 2021.[Methods]The data of cancer inci-dence,mortality and population data reported by cancer registration areas in Zhejiang Province from 2000 to 2021 were collected.The crude incidence/mortality rates,age-standardized rates ad-justed by Chinese standard population(ASIRC,ASMRC)and world standard population(ASIRW,ASMRW),cumulative rates(0~74 years old),truncated rates(35~64 years old),proportion of fe-male breast cancer and age-specific rate were calculated.The average annual percentage change(AAPC)of female breast cancer incidence and mortality rates in Zhejiang from 2000 to 2021 was calculated using Joinpoint software.[Results]In 2021,there were 7 262 new cases of female breast cancer in Zhejiang cancer registration areas,accounting for 12.70%of all new female can-cer cases.The crude incidence rate,ASIRC and ASIRW were 65.71/105,42.03/105 and 39.22/105,respectively.The cumulative incidence rate(0~74 years old)was 4.26%,and the truncated rate(35~64 years old)was 98.34/105.The ASIRC in urban and rural areas were 43.15/105 and 40.15/105,respectively.There were 992 deaths of female breast cancer,accounting for 6.97%of all female cancer deaths.The crude mortality rate,ASMRC and ASMRW were 8.98/105,4.62/105 and 4.47/105,respectively.The cumulative mortality rate(0~74 years old)was 0.48%,and the truncated rate(35~64 years old)was 8.89/105.The ASMRC in urban and rural areas were 4.79/105 and 4.34/105,respectively.The incidence rate of female breast cancer reached the peak at the age group of 60~64 years old,and the mortality rate reached the peak at the age group of 85 years old and above.From 2000 to 2021,the crude incidence rate,ASIRC and ASIRW of female breast cancer in Zhejiang cancer registration areas showed significant increasing trends(all P<0.05).The crude mortality rate and ASMRW of female breast cancer also showed significant increasing trends(all P<0.05).[Conclusion]The incidence rate of female breast cancer in Zhejiang Province was higher than the national average,while the mortality rate was lower than the national average in 2021.Both the incidence and mortality rates showed increasing trends from 2000 to 2021.Fur-thermore,distinct urban-rural disparities existed in both incidence and mortality characteristics.
6.Analysis of Serum Metabolic Biomarkers in Adult Patients with Kashin-Beck Disease and Degenerative Osteoarthritis in Qinghai Province.
Jia le XU ; Qiang LI ; Chuan LU ; Xin ZHOU ; Yan Mei ZHAO ; Jian Ling WANG ; Ji Quan LI ; Li MA ; Zhi Jun ZHAO ; Ke Wen LI
Biomedical and Environmental Sciences 2025;38(9):1173-1177
7.A case of chronic total occlusion of coronary arteries opened by reverse guidewire technology with ipsilateral brachioradial artery combined approach
Zhao-kun MA ; Cheng-yi XU ; Ya-feng GUO ; Dong YI ; Zheng-le YANG ; Hua YAN
Chinese Journal of Interventional Cardiology 2025;33(10):597-600
Intra-aortic balloon pump(IABP),as the most commonly used percutaneous mechanical circulatory assist device,is routinely implanted through the femoral artery pathway.However,when implantation through the femoral artery pathway is difficult or contraindicated,other pathways including the brachial artery pathway,axillary artery pathway,etc.can be considered.IABP assisted interventional treatment for complex high-risk and indicated patients(CHIP)can reduce the risk of intraoperative complications,stabilize hemodynamics,increase the complete revascularization rate of CHIP,and improve long-term prognosis.The reverse guidewire technique can improve the success rate of percutaneous coronary intervention(PCI)for chronic total occlusion(CTO)of coronary arteries.In clinical practice,the reverse pathway is often chosen in addition to the forward pathway,such as the contralateral radial and brachial artery pathway,femoral artery pathway,etc.This article reports a case of bilateral femoral artery occlusion,in which IABP was implanted through the left brachial artery pathway,and then with the assistance of IABP,the right coronary artery CTO lesion was successfully opened through the right radial artery in the forward direction and the right brachial artery in the reverse direction,with the aim of providing reference for clinical PCI treatment for such special cases.
8.Incidence and Mortality of Female Breast Cancer in Zhejiang Cancer Registration Areas in 2021 and Trends from 2000 to 2021
Yan LI ; Hongrui HUANG ; Xu MA ; Dan LUO ; Le WANG ; Huizhang LI ; Lingbin DU ; Yiping WU ; Yanfei QIU
China Cancer 2025;34(10):764-774
[Purpose]To analyze the incidence and mortality of female breast cancer in Zhejiang cancer registration areas in 2021 and the trends from 2000 to 2021.[Methods]The data of cancer inci-dence,mortality and population data reported by cancer registration areas in Zhejiang Province from 2000 to 2021 were collected.The crude incidence/mortality rates,age-standardized rates ad-justed by Chinese standard population(ASIRC,ASMRC)and world standard population(ASIRW,ASMRW),cumulative rates(0~74 years old),truncated rates(35~64 years old),proportion of fe-male breast cancer and age-specific rate were calculated.The average annual percentage change(AAPC)of female breast cancer incidence and mortality rates in Zhejiang from 2000 to 2021 was calculated using Joinpoint software.[Results]In 2021,there were 7 262 new cases of female breast cancer in Zhejiang cancer registration areas,accounting for 12.70%of all new female can-cer cases.The crude incidence rate,ASIRC and ASIRW were 65.71/105,42.03/105 and 39.22/105,respectively.The cumulative incidence rate(0~74 years old)was 4.26%,and the truncated rate(35~64 years old)was 98.34/105.The ASIRC in urban and rural areas were 43.15/105 and 40.15/105,respectively.There were 992 deaths of female breast cancer,accounting for 6.97%of all female cancer deaths.The crude mortality rate,ASMRC and ASMRW were 8.98/105,4.62/105 and 4.47/105,respectively.The cumulative mortality rate(0~74 years old)was 0.48%,and the truncated rate(35~64 years old)was 8.89/105.The ASMRC in urban and rural areas were 4.79/105 and 4.34/105,respectively.The incidence rate of female breast cancer reached the peak at the age group of 60~64 years old,and the mortality rate reached the peak at the age group of 85 years old and above.From 2000 to 2021,the crude incidence rate,ASIRC and ASIRW of female breast cancer in Zhejiang cancer registration areas showed significant increasing trends(all P<0.05).The crude mortality rate and ASMRW of female breast cancer also showed significant increasing trends(all P<0.05).[Conclusion]The incidence rate of female breast cancer in Zhejiang Province was higher than the national average,while the mortality rate was lower than the national average in 2021.Both the incidence and mortality rates showed increasing trends from 2000 to 2021.Fur-thermore,distinct urban-rural disparities existed in both incidence and mortality characteristics.
9.The computer-aided diagnosis model of middle ear cholesteatoma based on integrated convolutional neural networks
Yutong ZHAO ; Ruixia MA ; Hailing REN ; Ningyu FENG ; Ning ZHANG ; Le WANG ; Yongchun LI ; Xueliang SHEN ; Jiao HE
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2025;60(5):511-519
Objective:Middle ear cholesteatoma is a common otolaryngological disease, and traditional diagnostic methods have certain limitations. This study aims to construct a computer-aided diagnosis model for middle ear cholesteatoma based on integrated convolutional neural networks (CNNs) to improve diagnostic accuracy and efficiency.Methods:Firstly, Data were collected from patients who visited the Department of Otorhinolaryngology Head and Neck Surgery at the First People′s Hospital of Yinchuan between January 2020 and December 2021. 8 000 temporal bone CT images were collected, including 5 000 images diagnosed pathologically as middle ear cholesteatoma and 3 000 normal images. A five-fold cross-validation method was used to divide the dataset into training and testing sets. Next, a transfer learning approach was used to initialize model parameters, and the AlexNet, GoogleNet, and ResNet networks were pre-trained to extract deep features from the images. Then, the Softmax classification algorithm was applied to classify the features, resulting in three independent classifiers. These classifiers were combined using an ensemble learning method with a weighted voting approach to obtain the final diagnostic results. Finally, the model was evaluated by comparing the ensemble classifier with individual classifiers to assess its accuracy, precision, sensitivity, specificity, and diagnostic time, and a comparison with low-mid-and high-experience physician groups was conducted to comprehensively evaluate the model′s diagnostic performance.Results:The experimental results showed that the model achieved an accuracy of 88.8%(178/200), precision of 92.9%,(112/120) sensitivity of 89.8%(108/120), and specificity of 88.1%(70/80). The average diagnostic time for individual patient temporal bone CT images was reduced to 2-3 seconds. Compared to the diagnostic results from low-mid-and high-experience physician groups, the model demonstrated significant advantages and effectively assisted clinicians in making rapid and accurate middle ear cholesteatoma diagnoses.Conclusion:The proposed middle ear cholesteatoma diagnostic model based on integrated convolutional neural networks exhibits high recognition accuracy and rapid diagnostic speed, significantly improving clinical diagnostic efficiency, especially in early screening and auxiliary diagnosis, making it of considerable value in clinical practice.
10.Clinical guideline for diagnosis and treatment of nonunion of osteoporotic vertebral fractures (version 2025)
Haipeng SI ; Le LI ; Junjie NIU ; Wencan ZHANG ; Fuxin WEI ; Jinqiu YUAN ; Qiang YANG ; Hongli WANG ; Guangchao WANG ; Shihong CHEN ; Yunzhen CHEN ; Xiaoguang CHENG ; Jianwen DONG ; Shiqing FENG ; Rui GU ; Yong HAI ; Tianyong HOU ; Bo HUANG ; Xiaobing JIANG ; Lei ZANG ; Chunhai LI ; Nianhu LI ; Hua LIN ; Hongjian LIU ; Peng LIU ; Xinyu LIU ; Sheng LU ; Shibao LU ; Chunshan LUO ; Lvy CHAOLIANG ; Lvy WEIJIA ; Xuexiao MA ; Wei MEI ; Chunyang MENG ; Cailiang SHEN ; Chunli SONG ; Ruoxian SONG ; Jiacan SU ; Honglin TENG ; Hui SHENG ; Beiyu WANG ; Bingwu WANG ; Liang WANG ; Xiangyang WANG ; Nan WU ; Guohua XU ; Yayi XIA ; Jin XU ; Youjia XU ; Jianzhong XU ; Cao YANG ; Maowei YANG ; Zibin YANG ; Xiaojian YE ; Hailong YU ; Xijie YU ; Hua YUE ; Zhili ZENG ; Xinli ZHAN ; Hui ZHANG ; Peixun ZHANG ; Wei ZHANG ; Zhenlin ZHANG ; Jianguo ZHANG ; Tengyue ZHU ; Qiang LIU ; Huilin YANG
Chinese Journal of Trauma 2025;41(10):932-945
Nonunion of osteoporotic vertebral fractures (OVF), predominantly affecting the elderly, can lead to intractable pain, vertebral collapse, progressive kyphotic deformity, and neurological impairment, significantly compromising patients′ quality of life. There exists considerable debate on diagnosis and management of OVF, encompassing key issues such as clinical diagnosis and staging criteria for nonunion, surgical indications and procedure selection, and postoperative rehabilitation planning. Currently, there lacks standardized clinical guideline and expert consensus on the diagnosis and management of OVF nonunion in China. To address this gap, Minimally Invasive Surgery Group of Chinese Orthopedic Association, Osteoporosis Committee of Chinese Association of Orthopedic Surgeons, Prevention and Rehabilitation Committee for Osteoporosis of Chinese Association of Rehabilitation Medicine and Minimally Invasive Orthopedic Surgery Branch of China Association for Geriatric Care jointly organized domestic experts in spinal surgery, endocrinology, and rehabilitation to formulate the Clinical guideline for the diagnosis and treatment for nonunion of osteoporotic vertebral fractures ( version 2025), based on existing literature and clinical experience and adhering to principles of scientific rigor and practicality. The guideline provided 13 evidence-based recommendations encompassing diagnosis and treatment of OVF nonunion, aiming to standardize its clinical management.

Result Analysis
Print
Save
E-mail